Month: October 2026

• ADT stockholders will receive $10.00 per share in cash, representing a 45.6% premium to ADT’s unaffected closing share price of $6.87 on October 27, 2026.
• The transaction brings together ADT’s security expertise, technology and nationwide network of professionals with Thrive Holdings’ long-term capital and engineering capabilities.
• Upon completion of the transaction, ADT will become a privately held company.
• Thrive Holdings’ permanent capital structure can support sustained investment in ADT’s products, technologies, capabilities and people over a long-term horizon.
• Thrive Holdings will uphold ADT’s longstanding commitment to protecting customer data, and ADT’s data protection and privacy policies will remain unchanged.

BOCA RATON, Fla. and NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT) (“ADT” or the “Company”), a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., and Thrive Holdings, a permanent capital holding company focused on investing in established businesses and advancing their capabilities through technology, today announced a definitive agreement under which Thrive Holdings will acquire ADT in an all-cash transaction. The agreement values ADT at approximately $7.6 billion in equity value and $15.3 billion in enterprise value.

Under the terms of the agreement, which ADT’s Board of Directors unanimously approved, ADT stockholders will receive $10.00 per share in cash upon completion. The per share price represents a premium of 45.6% to ADT’s unaffected closing share price on October 27, 2026, and 52.1% to its 30-day volume-weighted average share price ending on October 27, 2026.

The transaction would combine ADT’s more than 150 years of security experience, nationwide service network and customer trust with Thrive Holdings’ long-term capital and engineering capabilities. Thrive Holdings is a permanent capital holding company, which enables it to own and operate businesses over a long-term horizon. This ownership structure will provide ADT with greater flexibility to invest in its people and the development of new products and services.

“ADT is pleased to enter into this transaction, which recognizes the value built by our more than 12,000 employees and delivers an attractive cash premium to our stockholders,” said Jim DeVries, Chairman, President and Chief Executive Officer of ADT. “Our leadership in security is based on a legacy of trust, longstanding customer relationships and the dedication of our employees. With Thrive Holdings’ long-term capital and technology expertise, ADT will gain new opportunities to accelerate innovation, enhance the customer experience and bring greater peace of mind to even more homes and businesses.” 

“ADT has spent generations showing up for people when it matters most,” said Kareem Zaki, Partner at Thrive Holdings. “We intend to build on that foundation by strengthening ADT’s technology and product capabilities, with the capital and patience to invest over decades. Our ambition is to help ADT’s teams better serve customers and offer a seamless service with more actionable information for the professionals responding.”

Currently, more than 75 businesses across accounting, IT services and the built environment are part of Thrive Holdings. Following the closing of the transaction, ADT will form the foundation of Thrive Holdings’ smart home security business.

Thrive Holdings intends to support ADT’s management in pursuing long-term growth through continued investment in the Company’s people, products and services. Thrive Holdings’ engineering teams will work alongside ADT’s professionals to identify opportunities for technology to enhance the Company’s products and services and help its teams support customers more effectively.

ADT’s data and privacy policies will remain unchanged, and no new data sharing will occur without customer permission.

“Protecting customers’ homes also means protecting their data. Thrive Holdings is committed to upholding the highest standards of privacy and cybersecurity to protect the information that customers entrust to ADT,” said Anuj Mehndiratta, Partner at Thrive Holdings.

Transaction Terms and Timing

Financing commitments for the transaction have been solely provided by funds managed by affiliates of Apollo Global Management, Inc.

The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions, including approval by ADT’s stockholders and receipt of U.S. antitrust approval. The transaction is not subject to a financing condition.

Under the terms of the merger agreement, ADT, with the assistance of its financial advisors, may solicit proposals from third parties for a period of 30 days continuing until 11:59 p.m., New York City time, November 28, 2026, with a potential 10-day extension for certain parties that submit acquisition proposals during the initial go-shop period. There can be no assurance that the solicitation process will result in a superior proposal, and ADT does not intend to disclose developments with respect to the go-shop process unless and until it determines such disclosure is appropriate or otherwise required. ADT will have the right to terminate the merger agreement to enter into a superior proposal, subject to the terms and conditions of the merger agreement.

Until the transaction closes, ADT will continue to operate independently. Following completion, ADT will become privately held and its common stock will cease trading on the New York Stock Exchange.

Third Quarter 2026 Financial Results

As previously announced, ADT’s third quarter 2026 results will be issued on November 3, 2026, prior to market opening. The Company will share a summary of its results on a 10 a.m. ET conference call. In consideration of the announced transaction, the Company will not be taking questions on the call. The Company’s third quarter press release and investor presentation will be available on its investor relations website at investor.adt.com.

Advisors

Citi and Goldman Sachs & Co. LLC are serving as financial advisors to ADT, with Cravath, Swaine & Moore LLP serving as legal counsel. Edelman Smithfield is serving as strategic communications advisor to ADT. Evercore is serving as exclusive financial advisor to Thrive Holdings, with Kirkland & Ellis LLP serving as legal counsel.

About ADT Inc.

ADT is a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S. Through innovative offerings, unrivaled safety and a premium customer experience delivered by the largest network of smart home security professionals in the U.S., ADT empowers people to protect and connect to what matters most, every second, every day. For more information, visit ADT.com.

About Thrive Holdings

Thrive Holdings owns and operates businesses in critical industries. Its engineers and operators work directly with industry specialists to develop and deploy proprietary technology products within the businesses it owns. Thrive Holdings takes a long-term approach to ownership and reinvestment. Its businesses include Current in accounting and Shield in IT services. For more information, visit thriveholdings.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the Company’s expectations, plans, intentions, strategies or prospects, including expected benefits of the proposed transaction. Generally, the words “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” “sees,” “seeks,” “should,” “could,” “would,” “predicts,” “potential,” “strategy,” “future,” “opportunity,” “work toward,” “intends,” “guidance,” “confidence,” “positioned,” “design,” “strive,” “continue,” “track,” “look forward to” and similar expressions used in this release are intended to identify forward-looking statements. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements.

Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements.

These risks, uncertainties and changes in circumstances include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all; (ii) the failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction by the Company’s stockholders; (iii) the possibility that any or all of the various conditions to the consummation of the proposed transaction may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (iv) the possibility that competing offers or acquisition proposals for the Company will be made; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction, including in circumstances which would require the Company to pay a termination fee; (vi) the effect of the announcement or pendency of the proposed transaction on the Company’s ability to attract, motivate or retain key executives and employees, its ability to maintain relationships with its customers, suppliers and other business counterparties, or its operating results and business generally; (vii) risks related to the proposed transaction diverting management’s attention from the Company’s ongoing business operations; (viii) the risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay; and (ix) (A) any other risks or uncertainties discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”) and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 (the “Quarterly Reports”) filed by the Company with the Securities and Exchange Commission (the “SEC”), and, in particular, the risk factors set forth under the headings “Risk Factors” and the risks and uncertainties discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Annual Report and the Quarterly Reports and (B) other risk factors identified from time to time in other filings with the SEC. Filings with the SEC are available on the SEC’s website at http://www.sec.gov.

Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless required by law. Readers of this release are cautioned not to unduly rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this release.

Additional Information and Where to Find It

This release may be deemed to be solicitation material in respect of the proposed acquisition of the Company by Thrive Holdings. In connection with the proposed transaction, the Company intends to file relevant materials with the SEC, including the Company’s proxy statement in preliminary and definitive form. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE COMPANY’S PROXY STATEMENT (IF AND WHEN AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders are or will be able to obtain the documents (if and when available) free of charge either from the SEC’s website at www.sec.gov, or from the Company in the “Investor Relations” section of the Company’s website, which may be accessed at https://investor.adt.com, or upon request from the Company’s Investor Relations contacts.

Participants in the Solicitation

The Company and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be “participants” in the solicitation of proxies from stockholders of the Company in connection with the proposed transaction. Information about the Company’s directors and executive officers is set forth in the Company’s Proxy Statement on Schedule 14A for its 2026 Annual Meeting of Stockholders, which was filed with the SEC on April 14, 2026 (the “2026 Proxy”) (and available here). Please refer to the sections entitled “Compensation of Non-Employee Directors,” “Executive Compensation – Compensation Discussion and Analysis” and “Security Ownership of Certain Beneficial Owners and Management” in the 2026 Proxy. To the extent holdings of the Company’s securities by its directors or executive officers have changed since the amounts set forth in the 2026 Proxy, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, including the Form 4s filed by: Fawad Ahmad on May 5, 2026, May 12, 2026, July 9, 2026 and October 5, 2026; Todd Dernberger on July 9, 2026 and October 5, 2026; Thomas M. Gartland on May 29, 2026, July 9, 2026 and October 5, 2026; Tracey R. Griffin on May 29, 2026, July 9, 2026 and October 5, 2026; Daniel J. Houston on May 12, 2026, May 29, 2026, July 9, 2026 and October 5, 2026; Omar Khan on May 12, 2026; Jeffrey Likosar on June 2, 2026; Kimberly Miller on May 18, 2026, July 9, 2026 and October 5, 2026; Paul J. Smith on May 29, 2026, July 9, 2026 and October 5, 2026; Danielle Tiedt on May 29, 2026, July 9, 2026 and October 5, 2026; Matthew E. Winter on May 29, 2026, July 9, 2026 and October 5, 2026; Suzanne Yoon on May 29, 2026, July 9, 2026 and October 5, 2026; and Sigal Zarmi on May 29, 2026, July 9, 2026 and October 5, 2026. Additional information concerning the interests of the Company’s participants in the solicitation, which may, in some cases, be different than those of the Company’s stockholders generally, will be set forth in the Company’s proxy statement relating to the proposed transaction when it becomes available.

Investor Contacts
InvestorRelations@adt.com

Media Contacts
Media@adt.com
PR@thriveholdings.com

NEW YORK, NY, Oct. 29, 2026 (GLOBE NEWSWIRE) — Cyabra, Inc. (Nasdaq: CYAB) (“Cyabra” or the “Company”), a company whose artificial intelligence (“AI”)-powered platform helps governments and enterprises detect coordinated manipulation and protect digital trust, today announced that Dan Brahmy, Co-Founder and Chief Executive Officer of Cyabra, participated in an interview with “The Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio show.

During the interview, Mr. Brahmy discussed the growing threat of online disinformation and the increasing sophistication of fake accounts, bot networks and AI-generated content used to manipulate public opinion and influence digital conversations. He also highlighted Cyabra’s AI-powered narrative intelligence platform, which helps organizations identify coordinated inauthentic activity, uncover manipulated narratives, and better understand the sources and impact of online disinformation. The discussion also addressed the importance of protecting digital trust and the expanding need for advanced detection capabilities among government agencies, national security organizations, and global enterprises.

The interview is available through “The Big Biz Show,” which airs on cable television and streaming services, including Roku, as well as on radio through The Biz Talk Radio Network, Armed Forces Radio and iHeart Media.

To access the full interview, please click here.

Podcasts of the show are available on iHeart Radio, Apple Podcasts, Spreaker.com and TuneIn, as well as to subscribers of biztv.com or ytaclub.com.

About The Big Biz Show

Widely regarded as “Business with a Bite,” The Big Biz Show is an Emmy Award-winning nationally syndicated radio and TV program. The fast-talking, hard-hitting show is hosted by Bob “Sully” Sullivan, who is also a weekly contributor on the FOX Business Network. For more information, go to bigbizshow.com.

About Cyabra

Cyabra is an AI-powered narrative intelligence company that helps national security and defense organizations, government agencies, brands, communications agencies, and global enterprises restore trust and authenticity online by analyzing manipulated content, coordinated behaviors, and inauthentic actors. The platform helps teams understand who is operating, how activity is amplified, and where coordinated activity is shaping perception, translating evidence into clear mitigation steps. By reducing ambiguity and misdirected response, Cyabra enables proportionate, evidence-led action when clarity matters most.

For more information, visit www.cyabra.com

For additional Information, please contact:

Investors: ir@cyabra.com 

Media: pr@cyabra.com 

Strengthening Patent Portfolio Builds Competitive Moat Across Consumer Gaming, Enterprise, and Defense Markets

AUSTIN, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 27th U.S. patent, covering proprietary footwear technology designed to improve movement and traction on omni-directional treadmills.

The newly allowed patent reinforces the intellectual property underpinning Virtuix’s Omni One, its most advanced platform to date that enables natural, multi-directional physical movement within immersive virtual environments. The Omni One platform has received industry recognition, including awards for Best VR Interaction Product at both the 2025 and 2026 Auggie Awards, underscoring its leadership position in the market.

Virtuix’s patent portfolio now includes 27 U.S. patents, with five additional patents pending, covering all core aspects of its full-body simulation technology including hardware design, motion tracking, and content integration. This growing IP position creates meaningful barriers to entry in a category that is increasingly gaining momentum across gaming, enterprise, healthcare, and military simulation.

“Securing our 27th patent highlights the depth of innovation behind our platform and reinforces our leadership in full-body movement technology,” said Jan Goetgeluk, CEO of Virtuix. “We believe we are significantly ahead of any competition in this space, with a broad and defensible intellectual property portfolio that supports our growth.”

Virtuix continues to invest in research and development to advance immersive technologies that enable natural movement within virtual environments. The company’s growing patent portfolio supports its long-term strategy to scale full-body interaction across multiple high-growth markets.

About Virtuix

Virtuix Holdings Inc. (NASDAQ: VTIX) is a developer of AI-driven, full-body immersive simulation systems and the creator of the “Omni” omni-directional treadmill. Virtuix’s technology lets users physically move through virtual and AI-generated environments. The Company’s products are deployed across consumer entertainment, defense training and simulation, robotics, healthcare, research, and enterprise applications involving organizations including Meta, NASA, Tesla, KBR, and Sirica Therapeutics. The Company’s growing federal and defense footprint includes programs, deployments, and research initiatives involving the U.S. Army, Marine Corps, Navy, and Air Force.

Virtuix continues to expand the Omni brand from immersive entertainment into a broader, full-body simulation technology platform serving multiple commercial and government markets. For more information, visit virtuix.com or the Company’s new Investor Relations website at invest.virtuix.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s sales and expansion plans; plans to pursue and complete strategic acquisitions, including the potential transaction currently under negotiation; potential impacts of any acquisition on future revenues, operations, or shareholder value; and the Company’s position in the defense training market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business; risks related to government contracting, including contract cancellations, modifications, or funding changes; the uncertainties related to market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X

Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com

Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us

Management to host conference call and webcast at 4:30 pm ET on that day

BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, November 5^th, 2026 at 4:30pm EDT to discuss results for its quarter ended September 30, 2026 and to provide a corporate update. 

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator.

Date: November 5^th, 2026

Time: 4:30 PM Eastern Time

Participant Dial-in: 1-800-717-1738 Participant Dial-in (international): +1-646-307-1865

Conference ID: INMUNE

A live audio webcast of the call can be accessed by clicking here or using this link:

https://viavid.webcasts.com/starthere.jsp?ei=1779628&tp_key=6eb5414d70

A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through December 21st, 2026 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering pin no. 1166817.

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

1. CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA and EU EMA in 2026, alongside a planned U.S. Biologics License Application (BLA) submission.

2. XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to eliminate neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including  Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts: 
David Moss 
Chief Executive Officer 
(561) 710-0512 
info@inmunebio.com

Daniel Carlson 
Head of Investor Relations 
(415) 509-4590 
dcarlson@inmunebio.com

Repeat order from a leading Israeli defense industry company supports the integration of Maris-Tech’s video processing technology into UAV mission computers

Rehovot, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, artificial intelligence (“AI”), and video intelligence solutions for defense applications, today announced that it has received a follow-on order from a leading Israeli defense industry company for boards from its Neptune family, designed to integrate Maris-Tech’s video processing technology into mission computers for unmanned aerial vehicles (“UAVs”).

The repeat order follows previous deliveries to the same customer and reflects continued demand for Maris-Tech’s technology in defense applications.

The Neptune family of boards is designed to enable the integration of advanced video processing capabilities directly into UAV mission computers. By embedding video processing at the mission computer level, UAV manufacturers and system integrators can support the capture, processing, encoding, and transmission of video from onboard cameras within the aircraft’s existing computing architecture.

This approach allows video and AI processing to be integrated into the UAV’s core systems, supporting real-time video handling while considering the size, weight, and power constraints of airborne platforms. This level of integration is particularly relevant for UAV applications that require efficient onboard processing and reliable delivery of video intelligence.

Israel Bar, Chief Executive Officer of Maris-Tech, commented, “We appreciate the continued confidence of this customer in our technology. Follow-on orders are important to us because they reflect the ongoing use of our solutions in customer systems. We believe that the ability to integrate our video processing technology directly into UAV mission computers is increasingly important in meeting the evolving requirements of defense platforms.”

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it is discussing the anticipated fulfillment of the follow-on order, the expected integration and use of its Neptune family of boards in UAV mission computers, the potential benefits and capabilities of its Neptune technology, including its ability to support video and AI processing within UAV systems, its belief that the follow-on order reflects continued customer demand for its technology, and its expectations regarding the evolving requirements of defense platforms and the potential relevance of its technology to those requirements. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

Reports highlight Concentrix’ growing leadership in driving meaningful client outcomes across AI operations, compliance, and digital trust

NEWARK, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, announced today it has earned designations from Everest Group across four areas critical to modern business operations: fraud management, financial crime and compliance, trust and safety, and agentic operations. Together, these designations highlight the evolving needs of Concentrix’ clients and the innovative solutions being developed alongside them to address emerging risks, regulatory pressures, and new opportunities with AI.

Concentrix was positioned as a Leader in Everest Group’s inaugural 2026 Fraud Management Operations Services PEAK Matrix^® Assessment and achieved the highest designation in market impact among 20 providers evaluated. Fraud is becoming more sophisticated as real-time payments accelerate and AI lowers the barriers to increasingly complex attacks. In this environment, businesses need new ways to strengthen resilience while improving how fraud is identified and addressed. Everest Group highlighted Concentrix’ ability to bring together advanced technology, strategic partnerships, and operational expertise to help clients stay ahead of evolving threats.

This assessment follows Concentrix’ acquisition of CastleHill Managed Risk Solutions, which expanded the company’s capabilities across governance, risk, compliance, third-party risk management, and AI governance. By combining these capabilities with its global scale and deep operational knowledge, Concentrix helps organizations build trust, adapt more quickly to change, and manage risk in ways that support long-term business growth.

“Organizations today are facing a fundamentally different operating environment, in which AI is creating enormous opportunity while simultaneously introducing new risks, complexity, and expectations,” said Axel Mouquet, Senior Vice President of Global Practices, Concentrix. “Our clients are at the forefront of this shift, challenging us to think differently, move faster, and solve challenges that are redefining how businesses operate. These recognitions reflect our belief that the future belongs to organizations that can bring together humans, AI, and operations in practical ways that build trust and deliver results. We’re proud to be the partner that helps clients navigate that future.”

Concentrix was also named a Leader in Everest Group’s 2026 Trust and Safety Services PEAK Matrix^® Assessment, marking its sixth consecutive year in the Leaders category. As AI-generated content, platform abuse, and regulatory scrutiny reshape digital ecosystems, trust and safety has become a board-level priority. The Leader designation reflects Concentrix’ ability to blend specialized expertise, AI-enabled operations, and platform knowledge to support safer digital experiences at scale.

In addition, Everest Group named Concentrix a Star Performer in its 2026 Financial Crime and Compliance Operations Services PEAK Matrix^® Assessment and a Major Contender in its 2026 Banking and Financial Services Agentic Operations PEAK Matrix^® Assessment. Together, these distinctions reflect continued investment in the future of regulated operations, where AI, compliance, risk management, and intelligent automation are becoming increasingly interconnected.

Visit the company’s website for more information on Concentrix’ Financial Crime and Compliance services and Trust & Safety solutions.

Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.

About us: Powering a World That Works
Concentrix (NASDAQ: CNXC), is the Fortune 500® technology and services company, helping the world’s best brands create intelligent operations that perform in the real world. We design, build, and run integrated human and AI solutions, harnessing the insight from billions of real-world interactions to help 2000+ of the world’s most complex organizations solve their toughest business challenges. Backed by 20+ years of operational experience and battle tested AI, we’re the intelligent transformation partner that helps clients across every major industry move from ambition to measurable, scalable performance. Virtually everywhere. Visit concentrix.com to learn more. 

Media Contact:
Marketing & Communications
Concentrix Corporation
media@concentrix.com

From Fortune. ©2026 Fortune Media (USA) Corporation. All rights reserved. Used under license. Fortune and Fortune 500 are registered trademarks of Fortune Media (USA) Corporation and are used under license. Fortune and Fortune Media (USA) Corporation are not affiliated with, and do not endorse products or services of, Concentrix.

Safe Harbor Statement
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the company’s capabilities and positioning to deliver business outcomes and solve challenges for its clients, and statements that include words such as believe, expect, may, will, provide, could and should and other similar expressions. These forward-looking statements are inherently uncertain and involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the company’s ability to successfully execute its strategy, competitive conditions in the company’s industry, and other factors contained in the Company’s Annual Report on Form 10-K for the fiscal year ended November 30, 2025 filed with the Securities and Exchange Commission and subsequent SEC filings. We do not undertake a duty to update forward-looking statements, which speak only as of the date on which they are made.

Copyright 2026 Concentrix Corporation and its subsidiaries. All rights reserved. Concentrix, the Concentrix logo, and all other Concentrix company, product and services names and slogans are trademarks or registered trademarks of Concentrix Corporation and its subsidiaries.

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK^® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, November 6, and an oral presentation on November 7

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, October 29, 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present data from its Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive patients with metastatic uveal melanoma, in a poster and oral session at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

The poster and oral presentations will include additional safety and efficacy data. The Company will issue a release on Friday, November 6, at 12:00 p.m. ET / 5:00 p.m. UK time when the poster session starts.

Presentation details

Title: Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma (Abstract number: 1177)
Poster session: Poster Hall
Date and Time: Friday, November 6, 2026, 10:00 a.m. MST / 12:00 p.m. EST

Clinical oral abstract session: Session 2
Date and Time: Saturday, November 7, 2026, 1:45 p.m. MST / 3:45 p.m. EST

###

About ImmTAC^® molecules for cancer

Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognize and kill cancer cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on demonstrated T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of mutational burden or immune infiltration, tumors that are characterized as immune “cold” or having low mutation burden.

About the IMC-F106C-101 Phase 1/2 trial

IMC-F106C-101 is a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumors, including non-small cell lung and ovarian cancers, as well as uveal melanoma, evaluating brenetafusp both as monotherapy and in combination arms with standards-of-care. The Phase 1 dose escalation portion of the trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and pharmacokinetics of IMC-F106C (brenetafusp) both as monotherapy and in combination with standards-of-care. Brenetafusp is a bispecific protein built on Immunocore’s ImmTAC technology, and the Company’s first molecule to target the PRAME antigen.

About KIMMTRAK

KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.

IMPORTANT SAFETY INFORMATION

Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK, with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.

Skin Reactions

Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.

Elevated Liver Enzymes

Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.

Embryo-Fetal Toxicity

KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose.

The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in 39 countries, including the United States, European Union, Canada, Australia, and the United Kingdom.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “aim”, “continue”, “target” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the data from the Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These and other risks and uncertainties are described in greater detail in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 25, 2026, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.

Contact Information

Immunocore
Sébastien Desprez, Vice President, Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore

Ryan Baker, Vice President, Investor Relations
T: +1 (215) 384-4781
E: ryan.baker@immunocore.com

NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from its phase 2 PrTK05 clinical trial evaluating aglatimagene besadenovec (aglatimagene) in localized prostate cancer has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.

The presentation will feature longitudinal immune-profiling findings from PrTK05 (NCT07332000), together with biodistribution and viral shedding data, providing additional insights into the biological activity and characterization of aglatimagene in patients with localized intermediate-risk prostate cancer.

The poster presentation details are as follows:

Title: Longitudinal immune profiling in the PrTK05 trial of aglatimagene besadenovec plus valacyclovir with radiation therapy for localized intermediate-risk prostate cancer

Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics

Abstract Number: 1172

Session Date: Saturday, November 7, 2026

Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4, 5 and 6

About aglatimagene besadenovec

Aglatimagene besadenovec (aglatimagene), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) with results published in the Journal for ImmunoTherapy of Cancer, and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform and is currently in an ongoing phase 3 clinical trial in NSCLC. Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s nonclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

CARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the following investor conferences:

Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum – New York, NY

Date: November 11, 2026

Panel: Innovative Diagnostics for Attractive Immunology Applications at 10:30am ET

Craig-Hallum’s Alpha Select Conference – New York, NY

Date: November 17, 2026

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a specialized diagnostics company with an autoimmune platform that empowers physicians to make more confident decisions, earlier. Its flagship test, AVISE® CTD, provides diagnostic clarity in complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease. Based in San Diego County, California, Exagen operates a CLIA-certified, CAP-accredited rheumatology laboratory delivering precise, timely results to physicians and partners across healthcare and biopharma. Through ongoing research and innovation, Exagen is committed to advancing care for autoimmune disease.  

For more information, visit Exagen.com or follow Exagen on LinkedIn.

Investors:
Tina Jacobsen, CFA
IR@exagen.com

Spotlights ibex’s Industry-leading Growth and Culture in the Region

WASHINGTON, Oct. 29, 2026 (GLOBE NEWSWIRE) — ibex (NASDAQ: IBEX), a global leader in outsourced business services and AI-powered customer experience solutions, was recognized as Frost & Sullivan’s 2026 Central America and the Caribbean Customer Experience Management Services Company of the Year. This reflects ibex’s outstanding performance, innovative AI-enabled solutions, and people-first leadership philosophy across its global footprint.

The report also acknowledged ibex’s significant growth in Central America and the Caribbean over the past seven years, including revenue growth of over 150% from 2018 to 2025.

“ibex’s continued innovation, substantial growth in Central America and the Caribbean region, and its highly rated client engagements make it the clear choice for CX Company of the Year,” said Sebastian Menutti, industry director at Frost & Sullivan. “With its leadership position in deploying AI-powered solutions, including AI Agents at scale, ibex has firmly established itself as the benchmark for CX delivery and execution in this region.”

“This recognition belongs to our teams across Central America and the Caribbean who deliver exceptional experiences for our customers every day,” said Bob Dechant, CEO of ibex. “It’s a testament to our growth and confirms what we’ve always believed: the companies that will win in customer experience are those that seamlessly combine the power of AI with human connection across the end-to-end customer journey.”

Frost & Sullivan’s Company of the Year recognition is powered by its Best Practices Criteria: a rigorous analytical process that involves a detailed evaluation across two dimensions for each nominated company. ibex was measured by Visionary Innovation & Performance and Customer Impact, excelling in both categories.

“The Central America and Caribbean region is a highly competitive talent market for customer service professionals, and our award-winning culture and employee development and growth opportunities help differentiate ibex from the pack,” said David Afdahl, Chief Operating Officer at ibex. “We’re proud of our consistent growth and industry-best employee Net Promoter Score of 82 and delighted to be recognized as the CX leader in this key region.”

With growing operations in Nicaragua, Honduras, and Jamaica, ibex continues to strengthen its position as the business process outsourcing leader and employer of choice in the region. ibex was also recently ranked in the Top 10 Best Places to Work for Service Professionals in the Caribbean and Central America by Great Place to Work^®, and remains committed to investing in its people, driving innovation, and creating meaningful opportunities for professional growth.

About ibex

ibex is a global leader in outsourced business services and AI-powered customer experience solutions, enabling the world’s best brands to deliver truly differentiated experiences for their customers. Leveraging a global team of more than 40,000 human CX experts – powered by the best AI technology, decades of CX innovation, and deep business insights – ibex engineers seamless, end-to-end customer journeys from AI agents to human agents at scale across retail, e-commerce, healthcare, fintech, utilities, technology, logistics, and more. Discover more at ibex.co and connect with us on LinkedIn.

Media Contact
Dan Burris
ibex
Daniel.Burris@ibex.co

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99bb7ba1-0f73-4f22-af62-7e5790e4e745